112 related articles for article (PubMed ID: 35972407)
1. Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2022 Sep; 77(10):2772-2778. PubMed ID: 35972407
[TBL] [Abstract][Full Text] [Related]
2. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Gethers M; Chen I; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2022 Jun; 77(7):1931-1937. PubMed ID: 35411395
[TBL] [Abstract][Full Text] [Related]
5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
9. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Lasko MJ; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
[TBL] [Abstract][Full Text] [Related]
11. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
12.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
13. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
[TBL] [Abstract][Full Text] [Related]
15.
Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
[TBL] [Abstract][Full Text] [Related]
19. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
[TBL] [Abstract][Full Text] [Related]
20. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]